Bonesupport Holding AB (CHIX:BONEXS) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BONEXS Bonesupport Holding AB CHIX:BONEXS
75 GF Score
Price kr219.70
GF Value kr461.69
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Bonesupport Holding AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

CHIX:BONEXS
75GF Score
Bonesupport Holding AB CHIX:BONEXS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bonesupport Holding AB (CHIX:BONEXS) Overvalued in 2026?

Based on GuruFocus' analysis, Bonesupport Holding AB stock appears to be undervalued. The current stock price of kr219.70 is trading 52.4% below its estimated GF Value™ of kr461.69. GuruFocus considers Bonesupport Holding AB to be Significantly Undervalued.

Key valuation signals for CHIX:BONEXS:

  • Dividends Received:
  • GF Value™: kr461.69 vs. price of kr219.70 (52.4% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the CHIX:BONEXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bonesupport Holding AB Business Description

Address Scheelevagen 19, Lund, SWE, SE-223 70
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and commercializes injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. The products of the company focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: United States and Europe & Rest of the World (EUROW).
75GF Score

Get the complete analysis for CHIX:BONEXS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr219.70
Price
kr461.69
GF Value